Catalyst
Slingshot members are tracking this event:
CTI Biopharma (CTIC) Plans to Release Top-Line Results from Phase 3 PIX306 Trial in Q3 2018, Comparing PIXUVRI and Rituximab with Gemcitabine and Rituximab in Aggressive B-Cell Non-Hodgkin Lymphoma (NHL)
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| CTIC |
|
|
||||
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jul 09, 2018
Occurred Source:
http://investors.ctibiopharma.com/phoenix.zhtml?c=92775&p=irol-newsArticle&ID=2357334
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 3, Pix306, Pixuvri, Rituximab, Gemcitabine, Aggressive B-cell Non-hodgkin Lymphoma, Nhl
